AR081535A1 - Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso - Google Patents
Formulaciones liquidas oleosas estables listas para usar, su preparacion y usoInfo
- Publication number
- AR081535A1 AR081535A1 ARP110101298A ARP110101298A AR081535A1 AR 081535 A1 AR081535 A1 AR 081535A1 AR P110101298 A ARP110101298 A AR P110101298A AR P110101298 A ARP110101298 A AR P110101298A AR 081535 A1 AR081535 A1 AR 081535A1
- Authority
- AR
- Argentina
- Prior art keywords
- patients
- agent
- ready
- stable
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una formulación líquida oleosa estable lista para usar caracterizada porque comprende (i) un ingrediente farmacéutico activo que tiene propiedades hidrofóbicas y/o lipofílicas y/o que presenta problemas de estabilidad en ambientes acuosos, (ii) un vehículo oleoso en el cual se disuelve o se dispersa el ingrediente farmacéutico activo, que se selecciona entre los aceites vegetales, los aceites sintéticos y los ácidos grasos, o combinaciones de éstos; y opcionalmente uno o más componentes seleccionados entre un agente espesante/de suspensión, un antioxidante, con conservante, un agente floculante, un agente de estabilización superficial, un edulcorante, un agente saborizante, un emulsionante y un agente colorante, o combinaciones de éstos.Reivindicación 17: La formulación líquida oleosa estable lista para usar de acuerdo con cualquiera de las reivindicaciones 1 a 15, caracterizada porque puede usarse para el tratamiento médico de grupos de pacientes seleccionados entre (i) los pacientes pediátricos, (ii) los pacientes de la tercera edad, (iii) los pacientes que padecen disfagia o (iv) los pacientes que deben recibir su medicación por vía nasogástrica o a través de sondas gastrostómicas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010015143A DE102010015143A1 (de) | 2010-04-16 | 2010-04-16 | Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081535A1 true AR081535A1 (es) | 2012-10-03 |
Family
ID=44628325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101298A AR081535A1 (es) | 2010-04-16 | 2011-04-14 | Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130115294A1 (es) |
EP (2) | EP2558071A2 (es) |
AR (1) | AR081535A1 (es) |
AU (1) | AU2011241896B2 (es) |
CA (1) | CA2796581A1 (es) |
DE (1) | DE102010015143A1 (es) |
IL (1) | IL218113A0 (es) |
TW (1) | TW201210634A (es) |
WO (1) | WO2011128783A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877259B2 (en) | 2012-02-09 | 2014-11-04 | Mary Kay Inc. | Cosmetic formulation |
EP2874624B8 (en) | 2012-07-17 | 2019-10-02 | Bayer New Zealand Limited | Injectable antibiotic formulations and their methods of use |
US8568747B1 (en) * | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
GB201306720D0 (en) * | 2013-04-12 | 2013-05-29 | Special Products Ltd | Formulation |
EP3253211A4 (en) * | 2015-02-05 | 2018-10-31 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of edema |
CN113197851A (zh) * | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
US10172833B2 (en) | 2015-08-11 | 2019-01-08 | Insys Development Company, Inc. | Sublingual ondansetron spray |
US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
EP3500309A1 (en) * | 2016-08-17 | 2019-06-26 | Rosemont Pharmaceuticals Limited | Stable atorvastatin suspension composition |
EP3299017A1 (en) * | 2016-09-23 | 2018-03-28 | The Boots Company PLC | Formulation |
GB201804621D0 (en) | 2018-03-22 | 2018-05-09 | Bcm Specials Ltd | Formulation |
SG11202103284QA (en) * | 2018-10-25 | 2021-05-28 | Cindome Pharma Inc | Formulations containing deuterated domperidone |
CN111840227B (zh) * | 2020-08-31 | 2022-02-22 | 陕西九州制药有限责任公司 | 氨酚曲马多口服乳液及其制备方法 |
CN113952298B (zh) * | 2021-12-08 | 2023-02-17 | 江苏农牧科技职业学院 | 硫酸头孢喹肟纳米混悬液及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889709A (en) * | 1985-03-18 | 1989-12-26 | Product Resources International, Inc. | Aerosol foam with adsorbate and container containing same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
ES2153786B1 (es) * | 1999-06-10 | 2001-10-16 | S A L V A T Lab Sa | Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis. |
CA2392353A1 (en) * | 1999-11-22 | 2001-05-31 | Galephar Pharmaceutical Research, Inc. | Stable acid labile benzimidazole pharmaceutical compositions |
US20040202696A1 (en) * | 2003-04-14 | 2004-10-14 | Cts Chemical Industries Ltd. | Administration form for veterinary use |
EP1663173A1 (en) * | 2003-09-25 | 2006-06-07 | Natco Pharma Limited | Enteric soft gelatin capsule containing esomeprazole and method of preparation |
US20070014846A1 (en) * | 2003-10-10 | 2007-01-18 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and atorvastatin |
US20060024335A1 (en) * | 2004-07-29 | 2006-02-02 | Roger Stier E | Oral compositions which mask the bitter taste of a bitter-tasting agent |
EP1957085A2 (en) * | 2005-11-08 | 2008-08-20 | Ranbaxy Laboratories, Ltd. | Macrolides as anti-inflammatory agents |
FR2914188B1 (fr) * | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
-
2010
- 2010-04-16 DE DE102010015143A patent/DE102010015143A1/de not_active Withdrawn
-
2011
- 2011-04-14 AR ARP110101298A patent/AR081535A1/es unknown
- 2011-04-15 TW TW100113206A patent/TW201210634A/zh unknown
- 2011-04-18 CA CA2796581A patent/CA2796581A1/en not_active Abandoned
- 2011-04-18 EP EP11731080A patent/EP2558071A2/en not_active Withdrawn
- 2011-04-18 AU AU2011241896A patent/AU2011241896B2/en not_active Ceased
- 2011-04-18 EP EP13183542.3A patent/EP2674152A1/en not_active Withdrawn
- 2011-04-18 WO PCT/IB2011/001351 patent/WO2011128783A2/en active Application Filing
-
2012
- 2012-02-14 IL IL218113A patent/IL218113A0/en unknown
- 2012-10-11 US US13/649,744 patent/US20130115294A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2011128783A2 (en) | 2011-10-20 |
AU2011241896B2 (en) | 2013-09-26 |
DE102010015143A1 (de) | 2011-10-20 |
AU2011241896A1 (en) | 2012-11-22 |
WO2011128783A3 (en) | 2012-04-19 |
TW201210634A (en) | 2012-03-16 |
US20130115294A1 (en) | 2013-05-09 |
EP2558071A2 (en) | 2013-02-20 |
IL218113A0 (en) | 2012-04-30 |
EP2674152A1 (en) | 2013-12-18 |
CA2796581A1 (en) | 2011-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081535A1 (es) | Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso | |
CO2022002685A2 (es) | Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos | |
CL2019000431A1 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814) | |
PE20141297A1 (es) | Formulaciones peptidicas robustas de liberacion controlada | |
CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
UY30321A1 (es) | Procedimiento para preparar medicamentos caracterizado por el uso de derivados sustituidos de la 3-metil-7-(2-butin-1-il) xantina y aplicaciones | |
BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
BR112016018673A2 (pt) | Composições de sistemas de distribuição de nanoemulsão | |
CO2018003424A2 (es) | Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma” | |
AR059829A1 (es) | Sistemas estables de nanocapsulas para la administracion de moleculas activas | |
CL2022002084A1 (es) | Formulaciones farmacéuticas | |
CL2013003365A1 (es) | Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros. | |
PE20191714A1 (es) | Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso | |
PE20130045A1 (es) | FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS | |
AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
AR044050A1 (es) | Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos | |
PE20120584A1 (es) | Preparaciones farmaceuticas transdermicas | |
AR060784A1 (es) | Mezclas binarias de acido hialuronico y su uso terapeutico | |
BR112012015433B8 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
BR112022012216A2 (pt) | Formulação de cuidado de saúde sólida, formulação líquida para cuidado de saúde, e emulsão para cuidados de saúde | |
BR112017013471A2 (pt) | Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit. | |
PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
AR110250A1 (es) | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida | |
BR112012015016B8 (pt) | formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação | |
AR077490A1 (es) | Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |